Avenue Therapeutics, Inc. (ATXI)

NASDAQ: ATXI · IEX Real-Time Price · USD
1.35
-0.03 (-2.17%)
Feb 1, 2023, 10:49 AM EST - Market open
-2.17%
Market Cap 6.31M
Revenue (ttm) n/a
Net Income (ttm) -4.71M
Shares Out 4.78M
EPS (ttm) -3.75
PE Ratio n/a
Forward PE 17.99
Dividend n/a
Ex-Dividend Date n/a
Volume 95,756
Open 1.37
Previous Close 1.38
Day's Range 1.33 - 1.37
52-Week Range 1.06 - 18.75
Beta -0.62
Analysts Sell
Price Target n/a
Earnings Date n/a

About ATXI

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2017
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ATXI
Full Company Profile

Financial Performance

Financial Statements

News

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

NEW YORK, NY / ACCESSWIRE / January 31, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATX...

Other symbols: FBIO
21 hours ago - Accesswire

Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement

MIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...

22 hours ago - GlobeNewsWire

Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

MIAMI, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...

4 days ago - GlobeNewsWire

Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...

2 months ago - GlobeNewsWire

Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...

3 months ago - GlobeNewsWire

Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

NEW YORK, NY / ACCESSWIRE / October 12, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI). About Avenue Ther...

4 months ago - Accesswire

Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...

4 months ago - GlobeNewsWire

What In The World Is Going On With Avenue Therapeutics Stock?

Avenue Therapeutics Inc (NASDAQ: ATXI) shares are trading lower by 62.64% to $2.35 Friday morning after the company priced a roughly 3.6 million unit offering at $3.30 per unit.

4 months ago - Benzinga

Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering

NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...

4 months ago - GlobeNewsWire

ATXI Stock Alert: What to Know as Avenue Therapeutics Soars 150%

It's been another bumpy day in the stock market, with many stocks opening higher only to lose momentum this afternoon. That said, some companies are outperforming meaningfully today.

4 months ago - InvestorPlace

What Is Going on With Avenue Therapeutics (ATXI) Stock Today?

Source: Numstocker/Shutterstock.com Avenue Therapeutics (NASDAQ: ATXI) stock is seeing wild movement on Friday following a reverse stock split and regulatory update. Starting with that reverse stock ...

4 months ago - InvestorPlace

Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA

NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization o...

4 months ago - GlobeNewsWire

Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...

1 year ago - GlobeNewsWire

Avenue Therapeutics Stock Trading Halted Today

FDA Advisory Committee to review IV tramadol New Drug Application FDA Advisory Committee to review IV tramadol New Drug Application

1 year ago - GlobeNewsWire

Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)

NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therape...

1 year ago - Accesswire

Avenue Therapeutics Announces Closing of Public Offering of Common Stock

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today ...

1 year ago - GlobeNewsWire

Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock

NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...

1 year ago - GlobeNewsWire

Avenue Therapeutics Announces Exercise and Closing of Underwriter's Over-Allotment Option

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today ann...

1 year ago - GlobeNewsWire

Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)

NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Thera...

1 year ago - Accesswire

Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...

1 year ago - GlobeNewsWire

Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs

Office of New Drugs concludes that additional input is needed, and U.S. Food and Drug Administration will convene an Advisory Committee meeting Office of New Drugs concludes that additional input is n...

1 year ago - GlobeNewsWire

Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday

Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COV...

Other symbols: NVAX
1 year ago - Benzinga

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...

1 year ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such invest...

1 year ago - Newsfile Corp

Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?

Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon

1 year ago - Zacks Investment Research